X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
heart failure, systolic - drug therapy (335) 335
humans (335) 335
index medicus (240) 240
male (220) 220
female (208) 208
heart failure (193) 193
cardiac & cardiovascular systems (181) 181
aged (167) 167
middle aged (156) 156
treatment outcome (128) 128
heart failure, systolic - physiopathology (119) 119
mortality (106) 106
heart failure, systolic - mortality (99) 99
adrenergic beta-antagonists - therapeutic use (85) 85
cardiovascular (75) 75
aged, 80 and over (59) 59
prognosis (58) 58
chronic disease (55) 55
angiotensin-converting enzyme inhibitors - therapeutic use (51) 51
follow-up studies (50) 50
abridged index medicus (48) 48
cardiac patients (47) 47
heart failure, systolic - diagnosis (46) 46
survival (46) 46
hospitalization (45) 45
trial (43) 43
adult (41) 41
cardiovascular agents - therapeutic use (41) 41
heart rate - drug effects (41) 41
medicine, general & internal (41) 41
outcomes (40) 40
prospective studies (40) 40
stroke volume - drug effects (40) 40
benzazepines - therapeutic use (39) 39
double-blind method (39) 39
care and treatment (37) 37
retrospective studies (36) 36
carvedilol (35) 35
drug therapy (35) 35
heart failure, systolic - complications (35) 35
randomized controlled trials as topic (35) 35
cardiotonic agents - therapeutic use (34) 34
risk factors (34) 34
systolic heart failure (34) 34
time factors (34) 34
association (33) 33
mineralocorticoid receptor antagonists - therapeutic use (32) 32
severity of illness index (32) 32
ventricular dysfunction, left - drug therapy (31) 31
dose-response relationship, drug (30) 30
heart failure, systolic - blood (30) 30
myocardial-infarction (30) 30
stroke volume (30) 30
ivabradine (29) 29
cardiology (28) 28
double-blind (28) 28
guidelines (28) 28
diagnosis (27) 27
morbidity (27) 27
heart rate (26) 26
internal medicine (26) 26
natriuretic peptide, brain - blood (26) 26
proportional hazards models (26) 26
propanolamines - therapeutic use (25) 25
ventricular function, left - drug effects (25) 25
dysfunction (24) 24
pharmacology & pharmacy (24) 24
adrenergic beta-antagonists - administration & dosage (23) 23
analysis (23) 23
angiotensin receptor antagonists - therapeutic use (23) 23
drug therapy, combination (23) 23
echocardiography (23) 23
hospitalization - statistics & numerical data (23) 23
therapy (23) 23
article (22) 22
carbazoles - therapeutic use (22) 22
left-ventricular dysfunction (22) 22
biomarkers - blood (20) 20
chronic heart failure (20) 20
rate reduction (20) 20
spironolactone - therapeutic use (20) 20
beta-blockers (19) 19
clinical medicine (19) 19
heart (19) 19
heart failure, systolic - epidemiology (19) 19
randomized-trial (19) 19
risk assessment (19) 19
ventricular dysfunction, left - physiopathology (19) 19
animals (18) 18
coronary-artery-disease (18) 18
digoxin (18) 18
disease (18) 18
diuretics - therapeutic use (18) 18
heart attacks (18) 18
heart failure, systolic - etiology (18) 18
kaplan-meier estimate (18) 18
klinisk medicin (18) 18
management (18) 18
medicine & public health (18) 18
natriuretic peptides (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (321) 321
German (5) 5
Czech (3) 3
Russian (3) 3
Japanese (2) 2
Chinese (1) 1
French (1) 1
Italian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 12/2009, Volume 120, Issue 22, pp. 2188 - 2196
Background-We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low... 
Drugs | Heart failure | Inflammation | Cholesterol | Risk factors | MORTALITY | SURVIVAL | heart failure | risk factors | CYTOKINES | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | drugs | TUMOR-NECROSIS-FACTOR | inflammation | CARDIOVASCULAR-DISEASE | cholesterol | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | PRIMARY PREVENTION | Heart Failure, Systolic - drug therapy | Heart Failure, Systolic - mortality | Humans | Risk Factors | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Rosuvastatin Calcium | Male | Randomized Controlled Trials as Topic | C-Reactive Protein - metabolism | Multicenter Studies as Topic | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Aged, 80 and over | Cholesterol, HDL - blood | Cholesterol, LDL - blood | Female | Aged | Retrospective Studies | Heart Failure, Systolic - blood | Fluorobenzenes - therapeutic use | Usage | Care and treatment | C-reactive protein | Physiological aspects | Rosuvastatin | Research | Health aspects | Statins | C-Reactive Protein | MEDICIN OCH HÄLSOVETENSKAP | 80 and over | HDL | Pyrimidines | LDL | Heart Failure | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | Fluorobenzenes | Hospitalization | Triglycerides | blood | statistics & numerical data | Sulfonamides | mortality | Systolic | metabolism | therapeutic use | Kaplan-Meiers Estimate
Journal Article
American Heart Journal, ISSN 0002-8703, 2012, Volume 164, Issue 5, pp. 793 - 799.e1
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9792, pp. 713 - 721
Journal Article
European Heart Journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 18, pp. 2290 - 2296
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2013, Volume 368, Issue 13, pp. 1210 - 1219
In this trial, patients with systolic heart failure and anemia were assigned to receive either darbepoetin alfa or placebo. At 28 months, there was no... 
MORTALITY | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | CITY CARDIOMYOPATHY QUESTIONNAIRE | EPOETIN | MORBIDITY | REDUCTION | DOUBLE-BLIND | CHRONIC KIDNEY-DISEASE | Shock, Septic - etiology | Double-Blind Method | Heart Failure, Systolic - drug therapy | Hematinics - therapeutic use | Erythropoietin - therapeutic use | Heart Failure, Systolic - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Erythropoietin - adverse effects | Hematinics - adverse effects | Male | Thromboembolism - etiology | Erythropoietin - analogs & derivatives | Stroke - etiology | Anemia - drug therapy | Treatment Failure | Female | Aged | Darbepoetin alfa | Anemia - etiology | Hemoglobins - analysis | Heart Failure, Systolic - complications | Heart failure | Usage | Care and treatment | Anemia | Patient outcomes | Diagnosis | Clinical trials | Patient safety | Hemoglobin | Thromboembolism | Patients | Heart diseases | Cancer | Shock | Systolic/mortality | Hematinics/adverse effects | chronic heart failure | Erythropoietin/analogs & derivatives | Thromboembolism/etiology | Klinisk medicin | Heart Failure | Anemia/drug therapy | Hematinics/therapeutic use | Erythropoietin/therapeutic use | Hemoglobins/analysis | Anemia/etiology | Erythropoietin/adverse effects | Stroke/etiology | Clinical Medicine | Systolic/complications | Septic/etiology | Systolic/drug therapy
Journal Article
Plos One, ISSN 1932-6203, 2012, Volume 7, Issue 3, pp. e33438 - e33438
BACKGROUND: Heart failure (HF) is a complex clinical syndrome characterized by impaired cardiac function and poor exercise tolerance. Enhanced inflammation is... 
STATEMENT | CAPACITY | THERAPY | PERFORMANCE | MULTIDISCIPLINARY SCIENCES | ACUTE MYOCARDIAL-INFARCTION | MICE | ECHOCARDIOGRAPHY | ANAKINRA | BETA-ADRENERGIC RESPONSIVENESS | LEFT-VENTRICULAR FUNCTION | Humans | Middle Aged | Myocardial Contraction - physiology | Myocardial Contraction - drug effects | Male | Exercise Tolerance - drug effects | Exercise Test | C-Reactive Protein - metabolism | Adult | Female | Interleukin 1 Receptor Antagonist Protein - pharmacology | Cytokines - blood | Disease Models, Animal | Interleukin-1beta - antagonists & inhibitors | Interleukin-1beta - physiology | Heart Failure, Systolic - drug therapy | Inflammation Mediators - blood | Ventricular Dysfunction, Left - etiology | Biomarkers - blood | Mice, Inbred ICR | Recombinant Proteins - administration & dosage | Ventricular Dysfunction, Left - physiopathology | Animals | Interleukin-1beta - administration & dosage | Ventricular Dysfunction, Left - drug therapy | Oxygen Consumption - drug effects | Exercise Tolerance - physiology | Heart Failure, Systolic - physiopathology | Mice | Heart failure | Heart | Development and progression | Inflammation | Interleukins | Heart attacks | Working groups | Interleukin | Isoproterenol | Epidemiology | Beta blockers | Reduction | Efficiency | Interleukin 1 | Pretreatment | Drug therapy | Cardiology | Heart diseases | Drug dosages | Physical therapy | Medical research | Task forces | Cytokines | Medicare | Internal medicine | Interleukin 1 receptor antagonist | Oxygen consumption | Pharmacology | Interdisciplinary aspects | Patients | Disease prevention | Intolerance | Signaling | Physical fitness | Exercise physiology | Councils | Pharmacy | Flow velocity | Rehabilitation | Ventricle
Journal Article